Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 9, 2014, Pages 2713-2720

  Nougarede, Nolwenn ^a   Bisceglia, Hélène ^a   Rozières, Aurore ^b,c,d   Goujon, Catherine ^e   Boudet, Florence ^a   Laurent, Philippe ^f   Vanbervliet, Beatrice ^b,c   Rodet, Karen ^b,c,e   Hennino, Ana ^b,c   Nicolas, Jean François ^b,c,d,e  

^a SANOFI PASTEUR   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c University Lyon i   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f Becton Dickinson Pharmaceutical Systems   (France)

Author keywords

Adult; Immunogenicity; Intradermal influenza vaccine; Intramuscular vaccination; Trivalent influenza vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; GEOMETRIC MEAN TITER; GEOMETRIC MEAN TITER RATIO; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOLOGICAL PARAMETERS; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; MALE; MEMORY CELL; MUCOSAL IMMUNITY; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SEROCONVERSION; SEROCONVERSION RATE; SEROPROTECTION RATE; SINGLE DRUG DOSE; TH1 CELL; TH2 CELL; VIRUS STRAIN; ADOLESCENT; B LYMPHOCYTE; BLOOD; COMPARATIVE STUDY; EUROPE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MONONUCLEAR CELL; SALIVA; SERUM; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; EUROPE; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; MALE; SALIVA; SERUM; YOUNG ADULT;

EID: 84920150889     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29695     Document Type: Article

References (38)

1. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20:2562-78; PMID:12057614; http://dx.doi.org/10.1016/S0264-410X(02)00154-8
2. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009; 58:446-58; PMID:19446340; http://dx.doi.org/10.1016/j.jinf.2009.04.001
3. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14;PMID:18844594; http://dx.doi.org/10.1586/14760584.7.8.1201
4. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002;109:1519-26; PMID:12070296; http://dx.doi.org/10.1172/JCI0215962
5. Le Borgne M, Dubois B, Kaiserlian D. Dendritic cells of mucosa and skin: "recruited for vaccination". Med Sci (Paris) 2007; 23:819-25; PMID:17937889; http://dx.doi.org/10.1051/medsci/20072310819
6. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, Harvey NG. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-42; PMID:18023942; http://dx.doi.org/10.1016/j.vaccine.2007.10.020
7. European Medicines Agency. Assessment report for Intanza®. London: European Medicines Agency, 2009.
8. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, Demanet E, Heijmans S, Van Belle P, Weber F, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; PMID:19341446; http://dx.doi.org/10.1186/1741-7015-7-13
9. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-9; PMID:18930093; http://dx.doi.org/10.1016/j.vaccine.2008.09.078
10. Duggan ST, Plosker GL. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years). Drugs Aging 2010; 27:597-605; PMID:20583853; http://dx.doi.org/10.2165/11203880-000000000-00000
11. Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10:134; PMID:20504306; http://dx.doi.org/10.1186/1471-2334-10-134
12. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:48-54; PMID:16494717; http://dx.doi.org/10.3201/eid1201.051237
13. Brandtzaeg P. Role of mucosal immunity in influenza. Dev Biol (Basel) 2003; 115:39-48; PMID:15088774
14. Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Medicines Agency, 1997.
15. Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, et al.; IMPAACT P1057 Team. Antiinfluenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010; 55:189-96; PMID:20581690; http://dx.doi.org/10.1097/QAI.0b013e3181e46308
16. Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755-63; PMID:17692438; http:// dx.doi.org/10.1016/j.vaccine.2007.06.066
17. Maecker HT, Rinfret A, D'Souza P, Darden J, Roig E, Landry C, Hayes P, Birungi J, Anzala O, Garcia M, et al. Standardization of cytokine flow cytometry assays. BMC Immunol 2005; 6:13; PMID:15978127; http://dx.doi.org/10.1186/1471-2172-6-13
18. Etchart N, Hennino A, Friede M, Dahel K, Dupouy M, Goujon-Henry C, Nicolas JF, Kaiserlian D. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007; 25:6891-9; PMID:17764789; http://dx.doi.org/10.1016/j.vaccine.2007.07.014
19. Co MD, Orphin L, Cruz J, Pazoles P, Rothman AL, Ennis FA, Terajima M. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 2008; 26:1990-8; PMID:18339461; http://dx.doi.org/10.1016/j.vaccine.2008.02.024
20. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80:11756-66; PMID:16971435; http://dx.doi.org/10.1128/JVI.01460-06
21. Zeman AM, Holmes TH, Stamatis S, Tu W, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007; 26:107-15; PMID:17259871; http://dx.doi.org/10.1097/01.inf.0000253251.03785.9b
22. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004; 57:236-47; PMID:15623947
23. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154:121-7; PMID:3711685; http://dx.doi.org/10.1093/infdis/154.1.121
24. el-Madhun AS, Cox RJ, Søreide A, Olofsson J, Haaheim LR. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 1998; 178:933-9; PMID:9806018; http://dx.doi.org/10.1086/515656
25. Beyer WE, Palache AM, Sprenger MJ, Hendriksen E, Tukker JJ, Darioli R, van der Water GL, Masurel N, Osterhaus AD. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996; 14:1331-9; PMID:9004442; http://dx.doi.org/10.1016/S0264-410X(96)00058-8
26. Ross TM, Lin CJ, Nowalk MP, Huang HH, Spencer SM, Shay DK, Sambhara S, Sundaram ME, Friedrich T, Sauereisen S, et al. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. Hum Vaccin Immunother 2014; 10:10; PMID:24614078; http://dx.doi.org/10.4161/hv.28313
27. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008; 3:e2975; PMID:18714352; http://dx. doi.org/10.1371/journal.pone.0002975
28. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One 2008; 3:e2574; PMID:18596908; http://dx.doi.org/10.1371/journal.pone.0002574
29. Dolfi DV, Mansfield KD, Kurupati RK, Kannan S, Doyle SA, Ertl HC, Schmader KE, Wherry EJ. Vac-cine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013; 8:e77164; PMID:24155927; http://dx.doi.org/10.1371/journal.pone.0077164
30. Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel) 2003; 115:9-16; PMID:15088770
31. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-74; PMID:8147099; http://dx.doi.org/10.1016/0264-410X(94)90056-6
32. Cheng LW, Huang SW, Huang LM, Chang LY, Shao PL, Kiang D, Wang JR. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine. J Virol Methods 2012; 182:43-9; PMID:22433514; http://dx.doi.org/10.1016/j.jviromet.2012.03.004
33. Ansaldi F,Canepa P,Ceravolo A,Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A (H3N2) influenza viruses. Vaccine 2012; 30:2908-13; PMID:22342501; http://dx.doi.org/10.1016/j.vaccine.2012.02.003
34. Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother 2013; 9:591-8; PMID:23295262; http://dx.doi.org/10.4161/hv.23240
35. Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35; PMID:22910287; http://dx.doi.org/10.1016/j.vaccine.2012.08.014
36. World Health Organization. WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva: World Health Organization, 2002.
37. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx.doi.org/10.1016/j.jim.2003.12.015
38. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857-72; PMID:9595616; http://dx.doi.org/10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E